کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2107334 | 1083669 | 2012 | 16 صفحه PDF | دانلود رایگان |

SummaryIt is unclear how cancer cells coordinate glycolysis and biosynthesis to support rapidly growing tumors. We found that the glycolytic enzyme phosphoglycerate mutase 1 (PGAM1), commonly upregulated in human cancers due to loss of TP53, contributes to biosynthesis regulation in part by controlling intracellular levels of its substrate, 3-phosphoglycerate (3-PG), and product, 2-phosphoglycerate (2-PG). 3-PG binds to and inhibits 6-phosphogluconate dehydrogenase in the oxidative pentose phosphate pathway (PPP), while 2-PG activates 3-phosphoglycerate dehydrogenase to provide feedback control of 3-PG levels. Inhibition of PGAM1 by shRNA or a small molecule inhibitor PGMI-004A results in increased 3-PG and decreased 2-PG levels in cancer cells, leading to significantly decreased glycolysis, PPP flux and biosynthesis, as well as attenuated cell proliferation and tumor growth.
► PGAM1 controls 3-PG and 2-PG levels to coordinate glycolysis and biosynthesis
► 3-PG binds to and inhibits 6PGD in the oxidative PPP
► 2-PG potentiates PHGDH to provide feedback control of 3-PG levels
► PGAM1 is a promising anticancer target
Journal: - Volume 22, Issue 5, 13 November 2012, Pages 585–600